کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
8787305 | 1601560 | 2016 | 5 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Vinflunina más trastuzumab en cáncer de vejiga Her2 positivo previamente tratado: reporte de un caso
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
موضوعات مرتبط
علوم پزشکی و سلامت
پزشکی و دندانپزشکی
تومور شناسی
پیش نمایش صفحه اول مقاله
چکیده انگلیسی
Bladder cancer is relatively common. In Mexico, in 2012, there were 3,245 new cases and 1,666 deaths in México. Platinum salt-based chemotherapy regimens are the standard first line treatment for metastatic disease. To date, no standard therapy has been established as second line, with the data being variable and unclear on this issue. Gemcitabine and Paclitaxel have been studied in this setting, with modest response rates. Vinflunine, a third-generation semi-synthetic vinca-alkaloid, appears to be a reasonable option for patients after first-line platinum-containing chemotherapy. Patients with advanced bladder cancer with over-expression of Her2, have a very poor prognosis. Nevertheless, the case is presented of a 54-year-old man with Her2 positive bladder cancer treated with Vinflunine plus Trastuzumab after recurrence with first-line adjuvant chemotherapy with cisplatin, who achieved a complete response and long-term disease control.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Gaceta Mexicana de OncologÃa - Volume 15, Issue 4, JulyâAugust 2016, Pages 240-244
Journal: Gaceta Mexicana de OncologÃa - Volume 15, Issue 4, JulyâAugust 2016, Pages 240-244
نویسندگان
Samuel Rivera Rivera, Juan Carlos Cásarez Price,